Henok Eyob

1.8k total citations · 1 hit paper
9 papers, 1.4k citations indexed

About

Henok Eyob is a scholar working on Molecular Biology, Immunology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Henok Eyob has authored 9 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Henok Eyob's work include Macrophage Migration Inhibitory Factor (3 papers), Cancer Mechanisms and Therapy (2 papers) and Phagocytosis and Immune Regulation (2 papers). Henok Eyob is often cited by papers focused on Macrophage Migration Inhibitory Factor (3 papers), Cancer Mechanisms and Therapy (2 papers) and Phagocytosis and Immune Regulation (2 papers). Henok Eyob collaborates with scholars based in United States and Taiwan. Henok Eyob's co-authors include Alicia Y. Zhou, Sanjeev Balakrishnan, Andrei Goga, Zena Werb, Kai Kessenbrock, Devon A. Lawson, Paul Yaswen, Chih‐Yang Wang, Karin D. Prummel and Ying Yu and has published in prestigious journals such as Nature, Nature Medicine and Cell Reports.

In The Last Decade

Henok Eyob

9 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

2015 690 citations Devon A. Lawson, Nirav R. Bhakta et al. Nature profile →

Peers

Henok Eyob

MB

CR

ONCOL

IMMUN

PRM

Elizabeth A. Kuczynski Canada

Pramudita R. Prasetyanti Netherlands

Marlous Hoogstraat Netherlands

Robert Lemos United States

Jeff C. Liu Canada

Sanjeev Balakrishnan United States

Salina Yuan United States

Caroline Delmas France

Catherine M. Shachaf United States

Elizabeth A. Kuczynski Canada

Henok Eyob

681 ×0.8

MB

454 ×0.7

CR

373 ×0.6

ONCOL

139 ×0.9

IMMUN

203 ×1.7

PRM

Citations per year, relative to Henok Eyob Henok Eyob (= 1×) peers Elizabeth A. Kuczynski

Countries citing papers authored by Henok Eyob

Since Specialization

Citations

This map shows the geographic impact of Henok Eyob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henok Eyob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henok Eyob more than expected).

Fields of papers citing papers by Henok Eyob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henok Eyob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henok Eyob. The network helps show where Henok Eyob may publish in the future.

Co-authorship network of co-authors of Henok Eyob

This figure shows the co-authorship network connecting the top 25 collaborators of Henok Eyob. A scholar is included among the top collaborators of Henok Eyob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henok Eyob. Henok Eyob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

P, Pavan Kumar, Yao Yu, Henok Eyob, et al.. (2021). Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation. Cell Reports. 35(9). 109156–109156. 17 indexed citations

2.

Camarda, Roman, Alicia Y. Zhou, Rebecca A. Kohnz, et al.. (2016). Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine. 22(4). 427–432. 396 indexed citations

3.

Horiuchi, Dai, Roman Camarda, Alicia Y. Zhou, et al.. (2016). PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine. 22(11). 1321–1329. 122 indexed citations

4.

Lawson, Devon A., Nirav R. Bhakta, Kai Kessenbrock, et al.. (2015). Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526(7571). 131–135. 690 indexed citations breakdown →

5.

Eyob, Henok, H. Atakan Ekiz, & Alana L. Welm. (2013). RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. OncoImmunology. 2(9). e25670–e25670. 16 indexed citations

6.

Eyob, Henok, H. Atakan Ekiz, Yoko S. DeRose, et al.. (2013). Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity. Cancer Discovery. 3(7). 751–760. 64 indexed citations

7.

Liu, Xuedong, Ling Zhao, Yoko S. DeRose, et al.. (2011). Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes & Cancer. 2(7). 753–762. 38 indexed citations

8.

Eyob, Henok, et al.. (2010). The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression. Current Drug Targets. 11(9). 1157–1168. 49 indexed citations

9.

Eyob, Henok, et al.. (2010). The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression. Current Drug Targets. 999(999). 1–12. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact